

Flavonoids and Gastric Cancer Therapy: From Signaling Pathway to Therapeutic Significance

Jiaying Cai^{1,*}, Xiyue Tan^{2,*}, Qichao Hu^{2,*}, Huafeng Pan³, Maoyuan Zhao⁴, Cui Guo⁴, Jinhao Zeng^{1,4,5}, Xiao Ma², Yanling Zhao⁶

¹School of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, People's Republic of China; ²State Key Laboratory of Southwestern Chinese Medicine Resources, School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, People's Republic of China; ³Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China; ⁴TCM Regulating Metabolic Diseases Key Laboratory of Sichuan Province, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, People's Republic of China; ⁵Department of Gastroenterology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, People's Republic of China; ⁶Department of Pharmacy, Chinese PLA General Hospital, Beijing, People's Republic of China

*These authors contributed equally to this work

Correspondence: Jinhao Zeng; Yanling Zhao, Email zengjinhao@cdutcm.edu.cn; zhaoyl2855@126.com

Abstract: Gastric cancer (GC) is a prevalent gastrointestinal tumor characterized by high mortality and recurrence rates. Current treatments often have limitations, prompting researchers to explore novel anti-tumor substances and develop new drugs. Flavonoids, natural compounds with diverse biological activities, are gaining increasing attention in this regard. We searched from PubMed, Web of Science, SpringerLink and other databases to find the relevant literature in the last two decades. Using “gastric cancer”, “stomach cancers”, “flavonoid”, “bioflavonoid”, “2-Phenyl-Chromene” as keywords, were searched, then analyzed and summarized the mechanism of flavonoids in the treatment of GC. It was revealed that the anti-tumor mechanism of flavonoids involves inhibiting tumor growth, proliferation, invasion, and metastasis, as well as inducing cell death through various processes such as apoptosis, autophagy, ferroptosis, and pyroptosis. Additionally, combining flavonoids with other chemotherapeutic agents like 5-FU and platinum compounds can potentially reduce chemoresistance. Flavonoids have also demonstrated enhanced biological activity when used in combination with other natural products. Consequently, this review proposes innovative perspectives for the development of flavonoids as new anti-GC agents.

Keywords: flavonoid, gastric cancer, apoptosis, angiogenesis

Introduction

Gastric cancer (GC) ranks as the fifth most prevalent cancer worldwide,¹ with approximately 990,000 new cases diagnosed annually.² It remains one of the leading causes of cancer-related deaths globally.³ While the overall incidence and mortality of GC have declined in most countries over the past few decades,^{4–6} the disease still poses a significant burden in Asia. GC development is influenced by various common factors, such as family history, diet, alcohol consumption, smoking, *Helicobacter pylori* infection, and Epstein Barr virus (EBV) infection.^{7–10} Controllable risk factors, including *H. pylori* infection, dietary habits and lifestyle, chemical radiation, or viral infections,^{11,12} can be addressed to potentially prevent GC. Currently, early-stage gastric cancers (GCs) are predominantly managed through endoscopic resection, whereas surgery is employed for non-early-stage operable tumors. Advanced GCs undergo a sequential chemotherapy regimen, typically involving platinum combined with fluoropyrimidine. Nevertheless, this treatment approach is associated with severe side effects, and the median survival rate is less than one year. Notably, cisplatin, a commonly used chemotherapeutic agent, has been linked to thromboembolic disease and renal dysfunction.¹³ Targeted therapies, such as trastuzumab, ramucirumab, and nivolumab or pembrolizumab, have also emerged as viable options in GC treatment. However, the diverse nature of GC among tumors, patients, and even within a single tumor poses a significant challenge to the development of effective targeted therapeutics.¹⁴ Consequently, there is a pressing

need for novel treatment regimens or drugs that can effectively manage GC patients while minimizing side effects and drug resistance.

Flavonoids are the most prevalent natural compounds found in plants, including *Leguminosae*, *Brassicaceae*, *Umbelliferae*, *Genisteinae*, *Loiaceae*, and various plant parts. Flavonoids typically refer to a group of compounds where two benzene rings, each containing phenolic hydroxyl groups, are interconnected by three central carbon atoms to form the C6-C3-C6 unit.^{15,16} They can be classified into 7 subclasses based on characteristics that include the degree of oxidation of the central three-carbon chain and the position of the B-ring attachment. Examples of these subclasses include chalcones, dihydrochalcones, flavones, and flavanols.^{17–19} Because of their abundance, flavonoids are commonly present in dietary fibers and find diverse applications in food and medicine.²⁰ Flavonoids in the diet can influence various molecular targets and signaling pathways related to cell growth, proliferation, differentiation, migration, angiogenesis, and hormone activity.^{21,22} This modulation contributes to the inhibition of different cancers, such as lung, liver, breast, and ovarian cancers.^{23–26}

Recent studies have increasingly demonstrated the beneficial effects of flavonoids on inhibiting GC. Numerous studies have provided evidence that flavonoids exert a regulatory role in modulating various phenotypes of GC, encompassing tumor growth, proliferation, invasion, metastasis, angiogenesis, and cell death (Figure 1). Therefore, our review tried to find the mechanism of flavonoids in the treatment of GC and provided new ideas for researchers.

Method

We searched from PubMed (<https://pubmed.ncbi.nlm.nih.gov/>), Web of Science (<http://apps.webofknowledge.com/>) SpringerLink (<https://link.springer.com/>) and other databases to search the literature in the last two decades. Using “gastric cancer”, “stomach cancers”, “flavonoid”, “bioflavonoid”, “2-Phenyl-Chromene” as keywords, were searched, then excluding literature unrelated to the topic.

The Bioactivity of Flavonoids

Extensive research has revealed that flavonoids possess diverse biological activities, including antioxidant, anti-inflammatory, and anticancer effects.^{27–29} Numerous mechanisms have been investigated to understand the antioxidant effects of flavonoids. These mechanisms include direct scavenging of oxides, activation of antioxidant enzymes, metal




Figure 1 The potential role of flavonoids for GC therapy. Flavonoids exert a regulatory role in modulating various phenotypes of GC, encompassing tumor growth, proliferation, invasion, metastasis, angiogenesis, and cell death. Created by Biorender.com.

chelating activity, attenuation of oxidative stress, inhibition of natriuretic oxidase, enhancement of antioxidant properties of low molecular weight antioxidants, elevation of uric acid levels, and elevation of deoxygenated oxygen radicals.³⁰ For example, fisetin has been found to inhibit xanthine oxidase activity and reduce oxidative damage.³¹ Flavonoids' anti-inflammatory effects often occur through the targeting of regulatory enzymes in signaling pathways, such as phosphatidylinositol kinase and protein kinase C.³² Additionally, flavonoids may exert anti-inflammatory effects by inhibiting transcription factors.²⁹ Many flavonoids also act as potent inhibitors of arachidonic acid, cyclooxygenase, and phospholipase A2, leading to a reduction in the production of prostaglandins, leukotrienes, and nitric oxide, all of which are key inflammatory substances.^{33–35} For instance, mulberry leaf flavonoids have been shown to decrease lipopolysaccharide-induced production of NO, PGE2, COX-2, and inflammatory factors in RAW 264.7 cells. Flavonoids' anticancer properties are frequently observed through their inhibitory effects on various types of cancer. Epigallocatechin and genistein, for instance, have been found to inhibit DNA methyltransferases and modify chromatin alterations in breast cancer.²⁵ Icaritin has been shown to enhance mitosis in hepatocellular cancer and synergistically promote immune cell death with doxorubicin.³⁶ Therefore, the current study suggests that flavonoids not only have diverse sources but also exhibit potent biological activities, making them attractive candidates for the development of new drugs (Figures 2 and 3).

Despite flavonoids are safe, some of them also have a prooxidative effect. For example, dietary phenolic substances have been shown to act as prooxidants in systems containing redox active metals. This indicates that different flavonoids may have opposite biological activities.

Flavonoids for Fighting Against GC

Recently, numerous flavonoids have been discovered to possess varying degrees of inhibitory effects on GC, with potential antitumor properties. These flavonoids have the ability to impact tumor growth and proliferation, inhibit tumor invasion and metastasis, affect angiogenesis, and induce cell death. Examining the antitumor effects of flavonoids from these perspectives could generate novel insights for drug development (Table 1).

Inhibition of Tumor Growth and Proliferation

A hallmark of tumorigenesis is the rapid growth and extensive proliferation capacity of tumors. Malignant tumors demonstrate virtually unlimited growth and proliferation, while benign tumors display more restricted expansion. Among the most prevalent natural compounds, flavonoids frequently exert inhibitory effects on the growth and proliferation of GC cells. For instance, farrerol (Figure 2, 2), a representative natural flavanone extracted from *Rhododendron dauricum* L., serves as an illustration. Treating SGC7901 cells with farrerol demonstrated its ability to suppress cancer cell growth by inducing sustained ERK activation-mediated G0/G1 phase cell cycle arrest and significantly upregulating the p27KIP1 protein.⁷¹ Additionally, isoliquiritigenin (Figure 2, 9), derived from licorice root, is a bioactive compound characterized by its chalcone structure.¹¹⁶ It possesses the capability to modulate the tumor microenvironment and inhibit tumor stemness, effectively suppressing GC stem-like properties by down-regulating GRP78 through CREB3L-mediated pathways.¹¹⁷

Furthermore, nano-encapsulation of chrysin (Figure 2, 7) in the PLGA-PEG-chrysin complex inhibited the growth of AGS cells. This inhibition was achieved by promoting increased expression of miR-22, miR-34a, and miR-126, resulting in the suppression of GC cell growth.⁶³ Nano-encapsulated bryostatin exhibited more consistent antitumor activity compared to the unencapsulated form.

In addition to influencing the cell cycle through miRNAs, flavonoids affect tumor growth by targeting various pathways. One commonly targeted pathway is the PI3K signaling pathway. For instance, scutellarin (Figure 2, 3) inhibited the growth and epithelial mesenchymal transition (EMT) of GC by up-regulating PTEN to inactivate the PI3K signaling pathway.¹⁰⁷ Similarly, iridin (Figure 2, 4) blocked the PI3K/AKT signaling pathway in AGS cells, leading to G2/M cell cycle arrest and affecting cancer cell proliferation.⁷⁹ Galangin (Figure 3, 39), a natural flavonol found in galangal, inhibited MGC-803 cells growth through the JAK2/STAT3 pathway, increasing ROS accumulation and reversing the abnormal expression of proteins such as p-JAK2, p-STAT3, Bcl-2, cleaved PARP, and Ki67. This induced apoptosis and reduced cell proliferation in GC cells.⁷³ Cardamonin (Figure 2, 1), a chalcone compound with effects




Figure 2 Chemical structures of representative flavonoids that prevent GC by modulating tumor growth, proliferation, invasion, metastasis, and angiogenesis. Created by Biorender.com.




Figure 3 Chemical structures of representative flavonoids that prevent GC by modulating cell death. Created by Biorender.com.

Table I Profiles of Flavonoids Inhibiting GC

Flavonoid	Source	Cell Line	Targets	Reference
Acacetin	<i>Verbascum lychnitis</i> (mullein)	AGS (in vitro)	↑Bax, p53; ↓Bcl-2	[37]
Afzelin	<i>Premna odorata</i> (fragrant premna)	MKN-45, MGC-803 (in vitro)	↓MMP2, MMP9	[38]
		AGS	↑GalNAcTL5; ↓ClGalTI	[39]
Alpinetin	<i>Zingiberaceae</i>	AGS, N-87	↑Bax; ↓Bcl-2	[40]
Amentoflavone	<i>Podocarpus elongatus</i>	AGS, HGC-27 (in vivo)	↑miR-496; ↓ATF2	[41]
Apigenin	<i>Verbascum lychnitis</i> (mullein)	AGS, SNU-216, NCI-N87, SNU-638, MKN-7, MKN-74	↓p-mTOR, p62, HIF-1 α , Ezh2	[42]
		HGC-27, SGC-7901	↑Caspase-3, Bax; ↓Bcl-2	[43]
		SGC-7901	Inhibits the cell proliferation	[44]
		MKN-45	↑MUC-2, I κ B α ; ↓NF- κ B	[45]
Apigetrin	<i>Galeopsis tetrahit</i> (hempnettle)	SGC-7901, MGC-803	↑Caspase-9/-3, Bax; ↓Bcl-2	[46]
		AGS	↑Caspase-3, PARP, LC3B-II, beclin-1; ↓CDK1, cyclin B1, cdc25c proteins	[47]
Baicalein	<i>Stachys annua</i> (annual hedgenettle)	HGC-27, SGC-7901	↓FAK, PI3K, AKT, mTOR	[48]
		AGS	↓N-cadherin, vimentin, ZEB1 and ZEB2	[49]
		HGC-27, SGC-7901, MGC-803, BGC-823	↑miR-7; ↓p-FAK	[50]
		SGC-7901	↑Bax; ↓Bcl-2	[51]
		HGC-27, AGS	↓PI3K, AKT	[52]
		SGC-7901, MGC-803	↓MMP-2/-9, p38	[53]
		AGS	↑PTEN; ↓Akt, HIF-1 α	[54]
		BGC-823, MGC-803	↑Caspase-9/-3, Bax; ↓Bcl-2	[55]
Baicalin	<i>Scutellaria amoena</i> (Scutellaria)	AGS (in vivo)	↓IL-1 β , IL-8, IgM, IgA	[56]
		AGS, SGC-7901	↑ROS	[57]
Casticin	<i>Fructus Vitis</i>	BGC-823, SGC-7901, MGC-803	↓cFLIP, Bcl-2, XIAP, survivin	[58]
Cardamonin	<i>Amomum subulatum</i>	AGS, MGC-803, BGC-823	↑Caspase-3, Bax; ↓Bcl-2	[59]
Chrysin	<i>Scutellaria amoena</i> (Scutellaria)	AGS	↑let-7a, miR-9, miR-22, miR-34a, miR-126; ↓miR-18, miR-21, miR-221	[60]
		SGC-7901, MKN-45, BGC-823	↑p53, E-cadherin; ↓COPB2	[61]
		MKN-45	↑TET1, 5hmC	[62]
		AGS	↑miR-22, miR-34a, miR-126	[63]
		AGS	↓MMP9	[64]
		AGS	↓NF- κ B, Egr-1	[65]
		SNU-484, AGS, MKN-28	↓AKT, HIF-1 α	[66]
		MKN28, AGS	↓RON	[67]
Deguelin	<i>Derris montana</i>			
EGCG	<i>Limoniastrum guyonianum</i> (Limonium)	SGC-7901	↓VEGF	[68]
		AGS	↓STAT6, VEGF	[69]
Farrerol	<i>Daphne aurantiaca</i>	SGC-7901	↑caspase-9/-3, Bax; ↓Bcl-2	[70]
		SGC-7901 (in vitro)	↑p27KIP1, ERK1/2, p38 MAPK	[71]

(Continued)

Table 1 (Continued).

Flavonoid	Source	Cell Line	Targets	Reference
Formononetin	<i>Pterocarpus indicus</i> (Purple sandalwood)	SGC-7901, MKN-45, MGC-803	↓SIRT1	[72]
Galangin	<i>Alpinia conchigera</i>	MGC-803	↑Caspase-3, Bax, PARP; ↓Bcl-2	[73]
		SNU-484	↑Caspase-9/-3, PARP	[74]
		MGC-803	↑LC3BII; ↓NF-κB	[75]
Hispidulin	<i>Eupatorium cannabinum</i> (hemp agrimony)	AGS	↑p21/WAF1, p16; ↓COX-2, cyclin D1/E	[76]
Icariin	<i>Epimedium pubescens</i>	BGC-823	↓Rac1, VASP	[77]
		SGC-7901, BGC-823, MKN-7, HGC-27, NUGC-3, AGS, Hs-746T, NCI-N87	↓Hsa_cir_0003159	[78]
Iridin	<i>Iris milesii</i>	AGS	↓Cdc25C, CDK1, Cyclin B1, p-PI3K, p-AKT	[79]
Irigenin	<i>Iris milesii</i>	NCI-N87	↑FADD, DR5, Bax	[80]
Isoliquiritigenin	<i>Pterocarpus indicus</i> (Purple sandalwood)	MKN-28	↑LC3II/LC3I, Beclin I	[81]
Isoquercitrin	<i>Apocynum venetum</i> L. (kender)	AGS, HGC-27	↑HMGB1, HSP70, HSP90	[82]
Isoorientin	<i>Carex fraseriana</i>	AGS	↓p-AKT, p-GSK-3β, β-catenin	[83]
Kurarinone	<i>Albizia julibrissin</i> (acacia)	SGC-7901	↑Mcl-1, c-FLIP	[84]
Liquiritin	<i>Polygonum aviculare</i> (knotgrass)	AGS, SNU-216	↑Caspase-9/-3, PARP	[85]
Licochalcone A	<i>Glycyrrhiza</i> (Licorice)	BGC-823	↑ROS, ERK, JNK	[86]
Licoflavone A	<i>Glycyrrhiza Glabra</i> (Licorice)	SGC-7901, MKN-45, MGC-803	↓VEGFR-2, PI3K/AKT, MEK/ERK	[87]
Luteolin	<i>Verbascum lychnitis</i>	MKN-45	↑Bax, Caspase-3, cytochrome C; ↓Bcl-2, p-Akt	[88]
		Hs-746T	↓VEGF	[89]
		Hs-746T, MKN-28	↓Notch1	[90]
		BGC-823, SGC-7901	↑miR-34a; ↓Bcl-2	[91]
		CRL-1739	↓MUC1, ADAM-17	[92]
		BGC-823	↑Caspase-9/-3, Bax; ↓Bcl-2	[93]
		SGC7901/DDP, BGC-823, HGC-27	↓Mcl-1, Survivin, Bcl-xl	[94]
		MKN-45, SGC-7901	↑Caspase-3, PARP-1; ↓MMP9, cMet	[95]
		AGS, BGC-823, SGC-7901	↓HK1, miR-34a	[96]
		HGC-27, MFC, MKN-45	↑ROS	[97]
Myricetin	<i>Ficus auriculata</i>	AGS	↓PI3K/Akt/mTOR	[98]
		HGC-27, SGC-7901	↑Mad1	[99]
Naringin	<i>Podocarpus fasciculus</i>	AGS	↑Bad; ↓Bcl-xL	[100]
		MGC-803, MKN-45	↑E-cadherin; ↓Zeb1, P-AKT	[101]
		SNU-1	↑Caspase-3, Bax; ↓Bcl-2	[102]
Naringenin	<i>Elaeodendron croceum</i>	SGC-7901	↑Caspase-3, Bax; ↓Bcl-2	[103]
Nobiletin	<i>Citrus tankan</i>	SGC-7901	↑Caspase-3; ↓Bcl-2, Survivin	[104]

(Continued)

Table 1 (Continued).

Flavonoid	Source	Cell Line	Targets	Reference
Pectolinarigenin	<i>Cirsium chanroenicum</i>	AGS, MKN-28	↓PI3K/AKT/mTOR	[105]
Quercetin	<i>Lotus ucrainicus</i>	AGS	↑CASP3, PARP	[106]
Scutellarin	<i>Erigeron breviscapus</i>	MGC-803, AGS	↑PTEN; ↓PI3K	[107]
Sanggenon C	<i>Morus cathayana</i> (voasun)	HGC-27, AGS	↓ERK	[108]
Silibinin	<i>Aspergillus iizukae</i>	SGC-7901	↑p53, p21; ↓p34cdc2	[109]
Wogonin	<i>Scutellaria likiangensis</i>	BGC-823, MGC-803, MKN-45, HGC-27	↑Caspase-3, Bax; ↓Bcl-2	[110]
		MGC-803	↓NF-κB	[111]
		SGC-7901	↓HIF-1α, MCT-4	[112]
Wogonoside	<i>Scutellaria discolor</i>	AGS, MKN-45	↑ASK1, JNK, Caspase-3/-9	[113]
Xanthohumol	<i>Humulus lupulus L.</i> (common hop)	AGS	↑ROS; ↓NF-κB	[114]
5-Hydroxy-3,6,7,8,3',4'-hexamethoxyflavone	<i>Macluradendron porteri</i>	BGC-7901	↑Caspase-3/-9, PARP, Bax/Bcl-2	[115]

similar to galangin (Figure 3, 39), affected GC cell (AGS, MGC-803, BGC-823) proliferation and the cell cycle by suppressing LncRNA-PVT1 expression, down-regulating p-STAT3, and inhibiting STAT3 activation.⁵⁹ Additionally, icariin (Figure 2, 5), a glycosidic flavonoid from the flavonol family, hindered the viability and growth of GC cells (SGC-7901, BGC-823, MKN-7, HGC-27, NUGC-3, AGS, Hs-746T, NCI-N87) by controlling the hsa_cir_0003159/miR-223-3p/NLRP3 axis.⁷⁸

In summary, the available research suggests that flavonoids inhibit the growth of GC cells through multiple pathways, particularly targeting PI3K, STAT, and other signaling pathways. These mechanisms encompass regulation of the cell cycle, gene expression, protein expression, and more, resulting in significant anti-growth and anti-proliferative effects (Figure 4).

Inhibition of Invasion and Metastasis

It is widely recognized that an increase in tumor aggressiveness and metastasis indicates unfavorable disease progression. One complication following surgery or chemotherapy is tumor metastasis, making it crucial to explore avenues for reducing tumor aggressiveness and inhibiting metastasis. EMT has been identified as a key player in tumor progression, invasion, and metastasis, enabling cancer cells to acquire increased aggressiveness.^{118,119} As a methoxyflavone, acacetin (Figure 3, 15) exhibited potent antitumor activity, primarily manifested in its ability to suppress tumor invasion and metastasis.^{120,121} Studies have demonstrated that acacetin inhibited the PI3K/Akt/Snail signaling pathway induced by TGF-β1-mediated EMT, leading to changes in the expression of EMT-related proteins and subsequently influencing the invasion and metastasis of GC.³⁸ Additionally, luteolin (Figure 3, 28) derived from various plants affects Notch1 signaling and EMT, which in turn inhibited tumor progression. When the Notch receptor binds to the ligand, the activated Notch intracellular domain (NICD) forms a complex with activated β-conjugated proteins. Luteolin blocked this complex formation and inhibited cell proliferation and metastasis, thereby impeding tumor progression.⁹⁰

Flavonoids, including baicalein (Figure 2, 6), isoliquiritigenin (Figure 2, 9), and others, not only affect EMT but also commonly inhibit the invasion and metastasis of GC cells by modulating the AKT/mTOR signaling pathway.^{48,81} The suppression of tumor invasion and metastasis by chrysin has garnered significant attention among the numerous flavonoids. Chrysin (Figure 2, 7) inhibited the phosphorylation of c-Jun and c-Fos in AGS cells by inhibiting the JNK1/2 and ERK1/2 signaling pathways. Consequently, it blocked AP-1 and regulated MMP-9 production, demonstrating an anti-invasive effect.⁶⁴ Ten-eleven translocation (TET) enzymes can catalyze the production of




Figure 4 Mechanisms of flavonoids suppressing GC by inhibiting tumor growth and proliferation, invasive migration, and angiogenesis. Created by Biorender.com.

5-hydroxymethylcytosine (5hmC).¹²² Previous studies have shown a reduction in TET3 and 5hmC expression in GC cells.¹²³ Researchers observed a significant increase in the expression of TET1 and 5hmC in chrysin-treated MKN-45 cells. Furthermore, the overexpression of TET1 promoted apoptosis and inhibited cell migration and invasion.⁶² Recepteur d'origine Nantais (RON), a member of the c-Met family, plays an important role in the progression, invasion, and metastasis of GC. Chrysin significantly inhibited the expression of RON by suppressing the activity of Egr-1 and NF- κ B transcription factors, thereby inhibiting cell invasion.⁶⁵ Consequently, based on the findings of this study, chrysin may possess an advantage in terms of drug selection for inhibiting GC invasion when compared to other flavonoids. Inhibiting EMT may serve as a promising therapeutic target for GC invasion (Figure 4).

Inhibition of Angiogenesis

Angiogenesis, an essential factor in cancer development and tumor metastasis, is associated with vascular endothelial growth factor (VEGF) and its receptor (VEGFR-2), making them important targets for treating GC. Moreover, natural compounds called flavonoids have been found to possess anti-angiogenic properties. *Scutellaria baicalensis*, a traditional Chinese medicine rich in flavonoids such as baicalein and wogonin,¹²⁴ exhibits both anticancer and antiviral properties. For instance, wogonin (Figure 2, 13) can suppress angiogenesis in SGC-7901 cells by downregulating HIF-1 α and MCT-4 expression.¹¹² Similarly, baicalein (Figure 2, 6) inhibited angiogenesis in GC by upregulating miR-7, leading to the blockade of the FAK/PI3K/AKT pathway. As a result, angiogenesis in GC (HGC-27, SGC-7901, MGC-803, BGC-823) was suppressed.⁵⁰ In addition to the aforementioned targets, VEGF and VEGFR-2, flavonoids such as licoflavone A (Figure 2, 12), luteolin (Figure 3, 28), and deguelin (Figure 2, 11) exhibit potent antitumor effects. Licoflavone A (Figure 2, 12) affected the proliferation, cycling, apoptosis, migration, invasion, and EMT of VEGF-stimulated MKN-

45 cells by targeting VEGFR-2 and inhibiting the PI3K/AKT and MEK/ERK signaling pathways.⁸⁷ Furthermore, in AGS cells, epigallocatechin-3-gallate (EGCG) (Figure 2, 14) suppressed IL-3-induced VEGF production and angiogenesis by reducing STAT6 activity, presenting a novel approach for anti-tumor angiogenesis.⁶⁹ Although studies have consistently identified the involvement of VEGF in tumor angiogenesis, further investigations are needed to elucidate the precise pathways and mechanisms (Figure 4).

Induction of Cell Death

During tumor development, cell death is an inevitable and significant aspect of the life cycle of cancer cells. Various forms of cell death, including necrosis, apoptosis, autophagy, ferroptosis, and pyroptosis, have been identified, each with distinct biological processes and pathophysiological characteristics.¹²⁵ Initially, research on flavonoids' mechanisms against GC cells primarily focused on understanding processes like apoptosis. Consequently, most current studies investigate the apoptotic effects induced by flavonoids and their impact on signaling pathways such as PI3K/AKT, TRAIL, and MAPK. However, as research progresses, a few studies have emerged exploring the induction of GC autophagy, ferroptosis, and pyroptosis by flavonoids (Figure 5).

Induction of Apoptosis

Targeting the PI3K/Akt Signaling Pathway

PI3Ks are a family of lipoprotein kinases capable of phosphorylating the 3-OH moiety of inositol phospholipids. They are classified into three classes: I, II, and III, with class I being more relevant to cancer. Akt proteins, important downstream of PI3K, regulate processes such as cell survival, cell cycle progression, and cell growth.^{126,127} In GC cells, the PI3K/AKT pathway, one of the most common pathways, is frequently studied to understand the mechanism of action of flavonoid agents.

Numerous flavonoids have been reported to induce apoptosis in GC cells through the PI3K/AKT signaling pathway. For instance, overexpression of the B-cell translocation gene 3 (BTG3) suppresses PI3K/AKT/mTOR pathway




Figure 5 Mechanisms of flavonoids suppressing GC by inducing cell death inducing apoptosis, autophagy, ferroptosis, and pyroptosis. Created by Biorender.com.

activation, thereby regulating GC cell proliferation, migration, and apoptosis.^{128,129} Baicalein (Figure 2, 6) inhibited the PI3K/AKT pathway by activating BTG3, resulting in endoplasmic reticulum stress (ERS) and apoptosis.⁵² Myricetin (Figure 3, 30), found in various natural plants including bayberry, induced apoptosis by inhibiting the PI3K/Akt/mTOR pathway, thereby reducing the expression of related proteins and affecting the viability of AGS cells.⁹⁸ Similarly, pectolinarigenin (Figure 3, 32), present in *Cirsium chanroenicum*, led to autophagy and apoptosis in AGS and MKN-28 cells by downregulating the PI3K/AKT/mTOR pathway.¹⁰⁵ Whereas apigetrin (Figure 3, 19)-treated AGS cells inhibited cancer progression by enhancing exogenous apoptosis and autophagic cell death via the PI3K/AKT/mTOR pathway.⁴⁷ Naringin (Figure 3, 38), isolated from citrus fruits, stimulated the expression of apoptosis-associated proteins Bax, decreased the expression of Bcl-2, and affected the apoptosis of SNU-1 cells by blocking the PI3K/AKT pathway.¹⁰² In another study, naringin (Figure 3, 38) was found to block the cell cycle, induced apoptosis, and inhibited the EMT process by inhibiting the PI3K-AKT/Zeb1 pathway in GC cells.¹⁰¹ These findings suggest that naringin has multiple targets on the PI3K/AKT signaling pathway, contributing to its multifaceted anti-tumor activities. In conclusion, various flavonoids can induce cell death by acting on the PI3K/AKT signaling pathway, indicating their potential against GC.

Targeting TRAIL Signaling Pathway

TRAIL is a pro-apoptotic protein that initiates apoptosis by binding to death receptors (DR).^{130,131} However, GC cells exhibit reduced sensitivity to TRAIL-induced apoptosis. Therefore, several scientific studies have focused on targeting TRAIL-induced apoptosis in GC cells using natural products like flavonoids. Liquiritin (Figure 3, 29) is a flavanone glycoside present in licorice,¹³² while irigenin (Figure 3, 23) is an isoflavonoid isolated from the roots of *Belamcanda chinensis*.¹³³ Both of them could induce apoptosis by sensitizing TRAIL, which in turn promoted the enhancement of pro-apoptotic proteins and the generation of ROS.^{80,85} Furthermore, casticin (Figure 3, 21), isolated from *Fructus Viticis*, enhanced TRAIL-induced apoptosis by down-regulating cell survival proteins and up-regulating the DR5 receptor via the ROS-ER stress-CHOP pathway.⁵⁸ Although there are limited studies on flavonoid-targeted TRAIL-induced apoptosis in GC, the current study presents a novel approach for GC treatment.

Targeting Bcl-2 Family

The Bcl-2 family plays a crucial role in apoptosis. Bcl-2, a pro-survival protein, regulates apoptosis by inhibiting the release of pro-apoptotic factors and the subsequent activation of the caspase cascade.¹³⁴ Flavonoids such as baicalin (Figure 3, 20), apigetrin (Figure 3, 19) and afzelin (Figure 3, 16) can interact with this protein.^{39,46,55} For instance, baicalin (Figure 3, 20) has been shown to induce apoptosis in BGC-823 and MGC-803 cells. This effect is achieved by up-regulating Bcl-2-associated X (Bax) protein, down-regulating Bcl-2, and activating caspase-3 and caspase-9 at both protein and mRNA levels.⁵⁵ Apigetrin (Figure 3, 19) acted as an apoptosis inducer by reducing Bcl-2 and enhancing Bax, caspase-9/-3, and PARP cleavage in SGC-7901, MGC-803.⁴⁶ In another study, afzelin (Figure 3, 16) was found to stimulate the apoptotic response by increasing the expression of Bax and caspase-8/-9/-3 mRNA, while simultaneously decreasing the expression of the extracellular structural domain of MUC1 (a transmembrane glycoprotein) and the extracellular expression of galectin-3 (a galactose-binding protein).³⁹ Therefore, targeting the Bcl-2 family is a potential pathway for flavonoids to combat GC.

Targeting MAPK Signaling Pathway

The mitogen-activated protein kinase (MAPK) signaling pathway is an evolutionarily conserved pathway that plays a vital role in carcinogenesis. It consists of five cascades: ERK1/2, SAPK/JNK, p38 MAPK, ERK5, and ERK3/4.¹³⁵ The MAPK pathway has been implicated in various cellular processes such as proliferation, differentiation, migration, senescence, and apoptosis.¹³⁶ Therefore, researchers have investigated the interplay between flavonoids' anticancer properties and the MAPK signaling pathway.

Isoorientin (Figure 3, 24), a C-glucosyl flavone naturally occurring in various foods and beverages, has been found to inhibit the p-ERK, p-STAT3, and NF- κ B signaling pathways through ROS-mediated MAPK/STAT3/NF- κ B signaling. This resulted in increased expression levels of STAT3 and NF- κ B and induced apoptosis in AGS cells.^{83,137} Likewise,

licochalcone A (Figure 3, 26) isolated from *Glycyrrhiza glabra* suppressed the MAPK signaling cascade, induced ROS generation and oxidative stress in BGC cells, leading to cell death.⁸⁶ In addition, luteolin (Figure 3, 28) inhibited the MAPK and PI16K signaling pathways at the mRNA level by up-regulating specific dual-specificity phosphatases and down-regulating chemokine (C-X-C motif) ligand 3, leading to apoptosis.⁹³ Therefore, these flavonoids have shown the potential to induce apoptosis and exhibit antitumor effects in GC cells through the modulation of the MAPK signaling pathway.

Induction of Autophagy

Autophagy is a process of programmed cell death whereby dead cells trigger the formation of autophagosomes, followed by degradation.^{138,139} There is increasing evidence supporting the role of flavonoids in inducing autophagy in GC cells. Notably, the citrus flavonoid naringin (Figure 3, 38) was found to induce autophagic cell death by promoting ROS production. This, in turn, activated the ERK1/2-p38 MAPK pathway and caused LMP-mediated lysosomal damage, ultimately leading to autophagy.¹⁰⁰ Similarly, treatment of AGS cells with apigenin (Figure 3, 18) resulted in increased autophagic cell death. This was evidenced by the upregulation of LC3B-II and beclin-1, the formation of autophagic vesicles and acidic vesicular organelles, as well as the elevated expression of the autophagic flux marker protein p62, all of which were induced by ERS.⁴⁷ Mechanistically, it has been reported that apigenin induced autophagic cell death in GC cells through the mTOR/AMPK/ULK1 pathway, leading to the down-regulation of p-mTOR, while increasing AMPK and ULK1 phosphorylation. Furthermore, under both normoxic and hypoxic conditions, apigenin induced ERS and autophagic cell death by inhibiting HIF-1 α and Ezh2.⁴² Conversely, in a tumor tissue model using nude mice, galangin (Figure 3, 39) reduced the phosphorylation level of proteins related to the NF- κ B signaling pathway, down-regulated the expression of the autophagy marker protein LC3B-I, up-regulated LC3B-II, and induced autophagy in MGC803 tumor tissues.⁷⁵

Induction of Ferroptosis and Pyroptosis

Ferroptosis is an iron-dependent, non-apoptotic form of cell death characterized by an accumulation of iron and ROS.^{125,140} Substances that induce ferroptosis can directly or indirectly modulate glutathione peroxidase, leading to a reduction in antioxidant capacity, an increase in ROS, and ultimately oxidative cell death.¹⁴¹ A limited number of studies have investigated the potential anti-GC activity of flavonoids through ferroptosis. For instance, baicalin (Figure 3, 20) promoted ROS-associated ferroptosis in AGS and SGC-7901 cells.⁵⁷ Amentoflavone (Figure 3, 40), a naturally occurring multifunctional biflavonoid, was found to inhibit activating transcription factor 2 (ATF2) by up-regulating miR-496 and subsequently malondialdehyde (MDA), ROS, and glutathione down-regulation. As a result, amentoflavone inhibited GC cell proliferation and induced ferroptosis.⁴¹

In contrast to ferroptosis, pyroptosis is an inflammatory vesicle-triggered, lysogenic programmed cell death characterized by cell swelling, lysis, and the release of various pro-inflammatory factors such as IL-1 β , IL-18, ATP, and HMGB1.^{142,143} In one study, quercetin (Figure 3, 41), a dietary flavonol, exerted its pyroptosis effect on AGS cells by activating the core pyroptosis gene and significantly upregulating the expression levels of pyroptosis makers (GSDMD, GSDME, Cleaved CASP1, NLRP3).¹⁰⁶ Although there are fewer studies investigating the impact of flavonoids on these two pathways, further research can explore additional flavonoids' effects on GC cell activity through ferroptosis and pyroptosis.

Combination with Other Drugs

In current treatments for GC, 5-FU and platinum compounds are frequently selected as chemotherapeutic agents. Consequently, combinations of these agents with flavonoids have emerged as a common approach to investigate their synergistic antitumor effects (Table 2).

Combination with 5-FU

5-FU, a uracil analog, functions by inhibiting thymidylate synthase, thus reducing DNA synthesis. It is widely employed as a chemotherapeutic drug in the treatment of GC.¹⁶⁴ However, the emergence of resistance poses a significant challenge

Table 2 Profiles of Flavonoids Combined Other Drugs Inhibiting GC

Flavonoid	Combination of Drugs	Cell Line	Targets	Reference
Baicalein	Baicalin, berberine chloride	AGS	↓IL-8, COX-2, iNOS	[144]
	Cisplatin	MGC-803, HGC-27, SGC-7901, SGC-7901/DDP	↑Nrf2; ↓Keap1, MDR1	[145]
	5-FU	AGS	↑PTEN; ↓HIF-1 α	[54]
Cardamonin	5-FU	BGC-823	↓P-glycoprotein, β -catenin, TCF4	[146]
Catechin	5-FU	SNU-620, SNU-620/5FU	↑Caspase-3, Bax; ↓Bcl-2	[147]
Chrysin	5-FU	AGS, AGS/FR	↓MDR1	[148]
Isoliquiritigenin	5-FU	MKN-45	↓GRP78	[117]
Licochalcone A	5-FU	SGC-7901, MKN-45	↑Caspase-3, Bax; ↓Bcl-2	[149]
Troloxerutin	5-FU	SGC-7901	↓STAT3/NF- κ B, Bcl-2	[150]
Kaempferol	Cisplatin/paclitaxel	AGS, SNU-216, NCI-N87, SNU-638	↑LC3-II; ↓G9a, p62	[151]
Liquiritin	Cisplatin	SGC7901/DDP (in vivo)	↑p53, p21; ↓cyclin D1, cyclin A, CDK4	[152]
Luteolin	Cisplatin	AGS	↑p21/cip1; ↓Cdc2, Cyclin B1, Cdc25C	[153]
	Oxaliplatin	SGC-7901	Inhibit cell proliferation	[154]
	Oxaliplatin	MFC	↑Bad; ↓Bcl-xL	[155]
Naringenin	ABT-737	SGC-7901	↑p53; ↓Akt	[156]
Nobiletin	Cisplatin	TMK-I, MKN-45, MKN-74, KATO-III	Inhibit cell proliferation	[157]
Quercetin	Irinotecan	AGS (in vivo)	↓VEGF	[158]
Rutin	Cisplatin, isoquercetin	AGS	Increase cytotoxicity	[159]
	Oxaliplatin	SGC-7901	↑p38/Caspase	[160]
	Lobetyolin, calycosin-7-glucoside	MGC-803, SGC-7901, BGC-823	↑HIF-1 α	[161]
	Quercetin, d-chiro-inositol	MGC-803	Inhibit cell proliferation	[162]
Wogonin	Oxaliplatin	BGC-823	↑JNK	[163]

in chemotherapy. Catechin, an antioxidant flavonoid predominantly found in woody plants as (+)-catechin and (-)-epicatechin¹⁶⁵, was found to effectively inhibit lactic acid production and lactate dehydrogenase A (LDHA) activity. It specifically targeted lactate dehydrogenase A to enhance the susceptibility of SNU620 GC cells to 5-FU.¹⁴⁷ This suggests that combining catechin with 5-FU enhances the cytotoxic effect on GC cells. Furthermore, similar resistance-reversing effects of flavonoids and 5-FU combinations were observed in other types of GC cells, such as AGS and MGS cells. For instance, the combination of chrysin (figure 2, 7) and 5-FU resulted in enhanced chemotherapeutic effects by blocking the G2/M phase in 5-FU-resistant AGS cells.¹⁴⁸ Under hypoxic conditions, baicalein (Figure 2, 6) inhibited glycolysis by modulating the PTEN/Akt/HIF-1 α signaling pathway and increased the sensitivity of AGS cells to 5-FU. It also reversed the resistance of cancer cells to 5-FU under hypoxic conditions.⁵⁴ In the case of MGC-803 cells, wogonin (Figure 2, 13) modulated metabolizing enzymes of 5-FU, prolonging catabolism and sensitizing MGC-803 cells to 5-FU-induced apoptosis by inhibiting NF- κ B nuclear translocation.¹¹¹ Additional studies on flavonoids combined with 5-FU in GC are listed in Table 2.^{117,146,149,150}

Combination with Platinum Compounds

Platinum compounds, being dominant and critical metalloids, find extensive application in the treatment of solid malignant tumors. They are commonly used in clinical practice as anticancer drugs for both monotherapy and combination therapy.^{166,167} However, flavonoids obtained from natural products often combine with platinum compounds to produce specific antitumor effects. For instance, when liquiritin (Figure 3, 29) and cisplatin were combined, they effectively induced apoptosis and autophagy both in vitro and in vivo in a GC cell model using nude mice. This combination enhanced the cleavage of caspase8/-9/-3 and PARP, as well as the expression of LC3B and Beclin 1.¹⁵²

Luteolin (Figure 3, 28) impaired the cellular mitochondrial membrane potential and hindered the growth and proliferation of GC cells when MFC cells were treated with low-dose oxaliplatin.¹⁵⁵ Additionally, wogonin (Figure 2, 13) enhanced not only the cytotoxic effect of 5-FU but also the cytotoxicity of oxaliplatin. Wogonin further aggravated the damage to the mitochondrial membrane potential induced by oxaliplatin in BGC-823 cells. Furthermore, when used in combination, wogonin allowed for a reduction in the dosage of oxaliplatin, thereby reducing the side effects of chemotherapeutic agents.¹⁶³ More flavonoids in conjunction with platinum chemicals for GC are listed in Table 2.^{145,151,153,154,157,159,160}

Combination with Other Natural Products

In addition to these two commonly used chemotherapeutic agents, flavonoids can be combined with other natural products to combat GC. For example, Hwanglyeonhaedok-tang, a traditional medicine, contains baicalein (Figure 2, 6) along with small amounts of alkaloids. This compound has been shown to inhibit *H. pylori* adhesion, as well as the increase of IL-8 and COX-2 in AGS cells.¹⁴⁴ Another example is Modified Spleen and Nutritional Soup, which contains mangostensin and rutin. These compounds have been found to inhibit GC progression by regulating tumor-associated macrophages and decreasing aerobic glycolysis in GC cells.¹⁶¹

Overall, these findings indicate that flavonoids alone possess certain antitumor effects on GC cells. However, when combined with chemotherapeutic drugs, they can help reduce drug resistance. Additionally, when combined with natural products, they can enhance their cytotoxic effects.

Discussion

GC, as a tumor with high morbidity and mortality, often faces major challenges in its treatment. We reviewed the mechanisms of action of flavonoids against gastric cancer from different pathways, such as inhibition of tumor growth and proliferation, invasion and metastasis, neovascularization, and induction of cell death. Several studies have found that flavonoids act on a variety of different biological pathways to inhibit GC, especially inducing cell death in gastric cancer. Flavonoids target pathways such as PI3K/Akt, TRAIL, MAPK, and the Bcl-2 family. In addition, it is worth our attention that flavonoids also act on common gastric cancer targets HER2, cMet, and VEGF. However, only some of the flavonoids have been found to inhibit these common gastric cancer targets, but the strength of the inhibitory effect needs to be verified by other experiments, and it remains to be explored whether other flavonoids also act on these targets. Moreover, compared with the studies that are associated with the signaling pathway, the research about flavonoids inhibiting HER2, Met, and PD-1 targets seems less, and even studies of flavonoids on Claudin 18.2 targets are lacking.

Flavonoids are mostly extracted from plants and often have multi-target effects. In addition to the common signaling pathways such as PI3K/Akt, there are some other targets that deserve our attention, one of which is short-chain ribonucleic acid. miR-7 and miR-496 are the two flavonoid drug targets that have been discovered so far, but their specific effects and strengths of action have not yet been explored. In addition, other solid tumor targets may be of interest. MUC1, a glycosylated type I transmembrane protein, is a potential drug target. Direct methods, including biotin labeling technology, click chemistry, and photocrosslinking reaction labeling technology, and indirect methods, including proteomics, metabolomics, and computer-aided drug design, are used for validation. Currently, there are many drug targets for gastric cancer, and the most common ones are HER2 and VEGF, which are mentioned above, but they are far from being sufficient for the treatment of tumors, so it is necessary to seek more new drug targets.

In addition to their antitumor effects through targeting, flavonoids may act in combination with other drugs. Most gastric cancers are insensitive to immune checkpoint inhibitor monotherapy, so patients with gastric cancer may need combination therapy to improve the response to immune checkpoint inhibitors. ADC drugs are a class of targeted biopharmaceuticals consisting of antibodies, linkers, and cytotoxic drugs, which can be used in tandem with small-molecule drugs to exert antitumor effects. Flavonoids are mostly natural small molecules, and more monomers have inhibitory effects on certain targets. Whether it is possible to develop flavonoids as new ADC drugs for gastric cancer treatment in the future, alone or in combination with PD-1 inhibitor K drugs, requires more research to explore.

However, even though there are more studies demonstrating the anticancer activity of flavonoids, their clinical aspects of research still need to be further deepened. In addition, age, gender, and genotype affect the absorption, distribution, metabolism, and elimination of flavonoids, resulting in low absorption, extensive metabolism, and rapid elimination,

which affects the bioavailability and bioactivity of flavonoids, among others. Moreover, flavonoids are categorized into different subgroups, including isoflavonols, flavanones, flavones, flavonols, anthocyanins, chalcones and so on. One of the representative compounds of flavonols is quercetin (Figure 3, 41), which may be detrimental to athletes, the elderly, or people with enzyme problems. Therefore, researchers should explore how to maximize the retention of flavonoids' bioactivity while reducing their side effects and maximizing the use of the drug in the future.

In conclusion, flavonoids have a wide range of biological effects, with particularly prominent anti-cancer effects. Due to the advantages of flavonoids' wide source, safety, and certain anticancer effects, in the future, flavonoids can be used in tumor therapy as drug formulations alone or in combination with existing antitumor drugs for multi-targeted or directed-targeted therapies. Therefore, flavonoids can be a good research direction for exploring GC therapeutic options and providing new possibilities for GC treatment.

Abbreviations

5hmC, 5-hydroxymethylcytosine; ASK1, apoptosis signal-regulating kinase 1; ATF2, activating transcription factor 2; ATF2, activating transcription factor 2; Bax, Bcl-2-associated X; BTG3, B-cell translocation gene 3; CDK1, cyclin-dependent kinase 1; cFLIP, cellular FLICE-like inhibitory protein; DR, death receptors; EBV, Epstein Barr virus; EGCG, epigallocatechin-3-gallate; EMT, epithelial mesenchymal transition; ERK, extracellular signal-regulated kinase; ERS, endoplasmic reticulum stress; EZH2, The enhancer of zeste homolog 2; FADD, Fas-associated protein with death domain; FAK, focal adhesion kinase; GC, gastric cancer; GCs, gastric cancers; *H. pylori*, *Helicobacter pylori*; HIF-1 α , hypoxia-inducible factor-1 α ; LDHA, lactate dehydrogenase A; MAPK, mitogen-activated protein kinase; MDA, malondialdehyde; MMP-9, matrix metalloproteinase 9; MUC, mucin; NICD, Notch intracellular domain; PARP, polymerase; PI3K, phosphatidylinositol 3 kinase; PTEN, phosphatase and tensin homolog; RON, Recepteur d'origine Nantais; SIRT1, silent information regulator 1; TET, ten-eleven translocation; VEGF, vascular endothelial growth factor.

Consent for Publication

All authors read and approved the final manuscript.

Acknowledgments

The authors would like to thank all reviewers and also the authors of all references. The reviewer's advice really makes the great improvement of this paper.

Author Contributions

All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

Funding

This paper was supported by the Major Program of the National Natural Science Foundation of China (82192915), National Natural Science Foundation of China (82274187) (82174346), Major scientific research problems and key topics of medical technology problems of China Medical Education Association (2022KTZ016), the Science and Technology Project of Sichuan Province (Grant No. 2022YFS0399), Xinglin Scholar Research Project of Chengdu University of TCM (Grant no. QJRC2022028)(Grant No. QJJJ2022010), the Program of Science and Technology Department of Sichuan Province (Grant No. 2023NSFSC0039) (grant no. 2023NSFSC1761), "Hundred Talents Program" of the Hospital of the Chengdu University of Traditional Chinese Medicine (Grant No. 22-B09), Young Elite Scientists Sponsorship Program by CACM (CACM-(2023-QNRC2-A01)).

Disclosure

All authors declare that there are no conflicts of interest and agree to publish this paper.

References

1. Ajani JA, D'Amico TA, Bentrem DJ, et al. Gastric cancer, version 2.2022, NCCN clinical practice guidelines in oncology. *J Natl Compr Canc Netw*. 2022;20(2):167–192.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. *Internat J Can*. 2010;127(12):2893–2917. doi:10.1002/ijc.25516
3. Ashrafizadeh M, Rafiei H, Mohammadinejad R, Farkhondeh T, Samarghandian S. Anti-tumor activity of resveratrol against gastric cancer: a review of recent advances with an emphasis on molecular pathways. *Cancer Cell Int*. 2021;21(1):66. doi:10.1186/s12935-021-01773-7
4. Arnold M, Park JY, Camargo MC, Lunet N, Forman D, Soerjomataram I. Is gastric cancer becoming a rare disease? A global assessment of predicted incidence trends to 2035. *Gut*. 2020;69(5):823–829. doi:10.1136/gutjnl-2019-320234
5. Ferro A, Peleteiro B, Malvezzi M, et al. Worldwide trends in gastric cancer mortality (1980–2011), with predictions to 2015, and incidence by subtype. *Eur J Cancer*. 2014;50(7):1330–1344. doi:10.1016/j.ejca.2014.01.029
6. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *Ca a Cancer J Clinicians*. 2021;71(3):209–249. doi:10.3322/caac.21660
7. Bouras E, Tsilidis KK, Triggs M, Siargkas A, Chourdakis M, Haidich AB. Diet and risk of gastric cancer: an umbrella review. *Nutrients*. 2022;14:9. doi:10.3390/nu14091764
8. Dong J, Thrift AP. Alcohol, smoking and risk of oesophago-gastric cancer. *Best practice & research. Clin Gastroenterol*. 2017;31(5):509–517. doi:10.1016/j.bpg.2017.09.002
9. Machlowska J, Baj J, Sitarz M, Maciejewski R, Sitarz R. Gastric cancer: epidemiology, risk factors, classification, genomic characteristics and treatment strategies. *Int J Mol Sci*. 2020;21(11):4012. doi:10.3390/ijms21114012
10. Wang F, Meng W, Wang B, Qiao L. Helicobacter pylori-induced gastric inflammation and gastric cancer. *Cancer Lett*. 2014;345(2):196–202. doi:10.1016/j.canlet.2013.08.016
11. Rawla P, Barsouk A. Epidemiology of gastric cancer: global trends, risk factors and prevention. *Prz Gastroenterol*. 2019;14(1):26–38. doi:10.5114/pg.2018.80001
12. Sun DQ, Yang F, Li H, et al. 1990—2019年胃癌发病率 and 死亡率变化趋势及地区差异 [Regional disparities in trends of global gastric cancer incidence and mortality from 1990 to 2019]. *Zhonghua zhong liu za zhi*. 2022;44(9):950–954. Chinese. doi:10.3760/cma.j.cn112152-20220120-00049
13. Yamada Y, Higuchi K, Nishikawa K, et al. Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer. *Anna Oncol*. 2015;26(1):141–148. doi:10.1093/annonc/mdl472
14. Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. *Lancet*. 2020;396(10251):635–648. doi:10.1016/S0140-6736(20)31288-5
15. Ullah A, Munir S, Badshah SL, et al. Important flavonoids and their role as a therapeutic agent. *Molecules*. 2020;25:22.
16. Badshah SL, Faisal S, Muhammad A, Poulson BG, Emwas AH, Jaremko M. Antiviral activities of flavonoids. *Biomed Pharmacothe*. 2021;140:111596. doi:10.1016/j.biopha.2021.111596
17. Pérez-Torres I, Castrejón-Téllez V, Soto ME, Rubio-Ruiz ME, Manzano-Pech L, Guarner-Lans V. Oxidative stress, plant natural antioxidants, and obesity. *Int J Mol Sci*. 2021;22(4):1786. doi:10.3390/ijms22041786
18. Sasaki N, Nakayama T. Achievements and perspectives in biochemistry concerning anthocyanin modification for blue flower coloration. *Plant Cell Physiol*. 2015;56(1):28–40. doi:10.1093/pcp/pcu097
19. Winkel-Shirley B. Flavonoid biosynthesis. A colorful model for genetics, biochemistry, cell biology, and biotechnology. *Plant Physiol*. 2001;126(2):485–493. doi:10.1104/pp.126.2.485
20. Kumar S, Pandey AK. Chemistry and biological activities of flavonoids: an overview. *TheScientificWorldJournal*. 2013;2013:162750. doi:10.1155/2013/162750
21. Chen Y, Tan X, Zhang W, et al. Natural products targeting macroautophagy signaling in hepatocellular carcinoma therapy: Recent evidence and perspectives. *Phytother Res*. 2024;38(3):1623–1650. doi: 10.1002/ptr.8103
22. Luo S, Huang M, Lu X, et al. Optimized therapeutic potential of Yinchenhao decoction for cholestatic hepatitis by combined network meta-analysis and network pharmacology. *Phytomedicine*. 2024;129:155573. doi: 10.1016/j.phymed.2024.155573
23. Jiang ZB, Wang WJ, Xu C, et al. Luteolin and its derivative apigenin suppress the inducible PD-L1 expression to improve anti-tumor immunity in KRAS-mutant lung cancer. *Cancer Lett*. 2021;515:36–48. doi:10.1016/j.canlet.2021.05.019
24. Jiang H, Yao Q, An Y, Fan L, Wang J, Li H. Baicalin suppresses the progression of Type 2 diabetes-induced liver tumor through regulating METTL3/m(6)A/HKDC1 axis and downstream p-JAK2/STAT1/cleaved Capase3 pathway. *Phytomedicine*. 2022;94:153823. doi:10.1016/j.phymed.2021.153823
25. Selvakumar P, Badgeley A, Murphy P, et al. Flavonoids and other polyphenols act as epigenetic modifiers in breast cancer. *Nutrients*. 2020;12:3. doi:10.3390/nu12030761
26. Banik K, Khatoun E, Harsha C, et al. Wogonin and its analogs for the prevention and treatment of cancer: a systematic review. *Phytother Res*. 2022;36(5):1854–1883. doi:10.1002/ptr.7386
27. Rodríguez-Arce E, Saldías M. Antioxidant properties of flavonoid metal complexes and their potential inclusion in the development of novel strategies for the treatment against neurodegenerative diseases. *Biomed Pharmacothe*. 2021;143:112236. doi:10.1016/j.biopha.2021.112236
28. Kopustinskiene DM, Jakstas V, Savickas A, Bernatoniene J. Flavonoids as Anticancer Agents. *Nutrients*. 2020;12:2. doi:10.3390/nu12020457
29. Maleki SJ, Crespo JF, Cabanillas B. Anti-inflammatory effects of flavonoids. *Food Chem*. 2019;299:125124. doi:10.1016/j.foodchem.2019.125124
30. Shen N, Wang T, Gan Q, Liu S, Wang L, Jin B. Plant flavonoids: classification, distribution, biosynthesis, and antioxidant activity. *Food Chem*. 2022;383:132531. doi:10.1016/j.foodchem.2022.132531
31. Zeng N, Zhang G, Hu X, Pan J, Gong D. Mechanism of fisetin suppressing superoxide anion and xanthine oxidase activity. *J Funct Food*. 2019;58:1–10. doi:10.1016/j.jff.2019.04.044
32. Hou DX, Kumamoto T. Flavonoids as protein kinase inhibitors for cancer chemoprevention: direct binding and molecular modeling. *Antioxid Redox Signaling*. 2010;13(5):691–719. doi:10.1089/ars.2009.2816

33. Kaushal N, Singh M, Singh Sangwan R. Flavonoids: food associations, therapeutic mechanisms, metabolism and nanoformulations. *Food Res Internat.* **2022**;157:111442. doi:10.1016/j.foodres.2022.111442
34. Hanáková Z, Hošek J, Kutil Z, et al. Anti-inflammatory activity of natural geranylated flavonoids: cyclooxygenase and lipoxygenase inhibitory properties and proteomic analysis. *J Natural Prod.* **2017**;80(4):999–1006. doi:10.1021/acs.jnatprod.6b01011
35. Zeinali M, Rezaee SA, Hosseinzadeh H. An overview on immunoregulatory and anti-inflammatory properties of chrysin and flavonoids substances. *Biomed Pharmacoth.* **2017**;92:998–1009. doi:10.1016/j.biopha.2017.06.003
36. Yu Z, Guo J, Hu M, Gao Y, Huang L. Icaritin exacerbates mitophagy and synergizes with doxorubicin to induce immunogenic cell death in hepatocellular carcinoma. *ACS nano.* **2020**;14(4):4816–4828. doi:10.1021/acsnano.0c00708
37. Pan MH, Lai CS, Hsu PC, Wang YJ. Acacetin induces apoptosis in human gastric carcinoma cells accompanied by activation of caspase cascades and production of reactive oxygen species. *J Agricul Food Chem.* **2005**;53(3):620–630. doi:10.1021/jf048430m
38. Zhang G, Li Z, Dong J, et al. Acacetin inhibits invasion, migration and TGF- β 1-induced EMT of gastric cancer cells through the PI3K/Akt/Snail pathway. *BMC Complement Med Therap.* **2022**;22(1):10. doi:10.1186/s12906-021-03494-w
39. Radziejewska I, Supruniuk K, Czarnomysy R, Buzun K, Bielawska A. Anti-cancer potential of afzelin towards AGS gastric cancer cells. *Pharmaceut.* **2021**;14(10). doi:10.3390/ph14100973
40. Wang Z, Lu W, Li Y, Tang B. Alpinetin promotes Bax translocation, induces apoptosis through the mitochondrial pathway and arrests human gastric cancer cells at the G2/M phase. *Molec Med Rep.* **2013**;7(3):915–920. doi:10.3892/mmr.2012.1243
41. Tang F, Xu Y, Gao E, et al. Amentoflavone attenuates cell proliferation and induces ferroptosis in human gastric cancer by miR-496/ATF2 axis. *Chem. Biol. Drug Des.* **2023**;102:782–792. doi:10.1111/cbdd.14288
42. Kim TW, Lee HG. Apigenin induces autophagy and cell death by targeting EZH2 under hypoxia conditions in gastric cancer cells. *Int J Mol Sci.* **2021**;22:24. doi:10.3390/ijms222413455
43. Chen J, Chen J, Li Z, Liu C, Yin L. The apoptotic effect of apigenin on human gastric carcinoma cells through mitochondrial signal pathway. *Tumour Biol.* **2014**;35(8):7719–7726. doi:10.1007/s13277-014-2014-x
44. Wu K, Yuan LH, Xia W. Inhibitory effects of apigenin on the growth of gastric carcinoma SGC-7901 cells. *World J Gastroenterol.* **2005**;11(29):4461–4464. doi:10.3748/wjg.v11.i29.4461
45. Wang YC, Huang KM. In vitro anti-inflammatory effect of apigenin in the Helicobacter pylori-infected gastric adenocarcinoma cells. *Food Chem Toxicol.* **2013**;53:376–383. doi:10.1016/j.fct.2012.12.018
46. Sun Q, Lu NN, Feng L. Apigenin inhibits gastric cancer progression through inducing apoptosis and regulating ROS-modulated STAT3/JAK2 pathway. *Biochem Biophys Res Commun.* **2018**;498(1):164–170. doi:10.1016/j.bbrc.2018.02.009
47. Kim SM, Vetrivel P, Ha SE, Kim HH, Kim JA, Kim GS. Apigenin induces extrinsic apoptosis, autophagy and G2/M phase cell cycle arrest through PI3K/AKT/mTOR pathway in AGS human gastric cancer cell. *J Nutr Biochem.* **2020**;83:108427. doi:10.1016/j.jnutbio.2020.108427
48. Qiao D, Jin J, Xing J, et al. Baicalein Inhibits Gastric Cancer Cell Proliferation and Migration through a FAK Interaction via AKT/mTOR Signaling. *Am J Chin Med.* **2021**;49(2):525–541. doi:10.1142/S0192415X21500245
49. Chen F, Zhuang M, Peng J, et al. Baicalein inhibits migration and invasion of gastric cancer cells through suppression of the TGF- β signaling pathway. *Molec Med Rep.* **2014**;10(4):1999–2003. doi:10.3892/mmr.2014.2452
50. Qiao D, Xing J, Duan Y, et al. The molecular mechanism of baicalein repressing progression of gastric cancer mediating miR-7/FAK/AKT signaling pathway. *Phytomedicine.* **2022**;100:154046. doi:10.1016/j.phymed.2022.154046
51. Mu J, Liu T, Jiang L, et al. The traditional Chinese medicine baicalein potently inhibits gastric cancer cells. *J Cancer.* **2016**;7(4):453–461. doi:10.7150/jca.13548
52. Shen J, Yang Z, Wu X, Yao G, Hou M. Baicalein facilitates gastric cancer cell apoptosis by triggering endoplasmic reticulum stress via repression of the PI3K/AKT pathway. *Appl Biol Chem.* **2023**;66(1):10. doi:10.1186/s13765-022-00759-x
53. Yan X, Rui X, Zhang K. Baicalein inhibits the invasion of gastric cancer cells by suppressing the activity of the p38 signaling pathway. *Oncol Rep.* **2015**;33(2):737–743. doi:10.3892/or.2014.3669
54. Chen F, Zhuang M, Zhong C, et al. Baicalein reverses hypoxia-induced 5-FU resistance in gastric cancer AGS cells through suppression of glycolysis and the PTEN/Akt/HIF-1 α signaling pathway. *Oncol Rep.* **2015**;33(1):457–463. doi:10.3892/or.2014.3550
55. Wang H, Li H, Chen F, et al. Baicalin extracted from Huangqin (Radix Scutellariae Baicalensis) induces apoptosis in gastric cancer cells by regulating B cell lymphoma (Bcl-2)/Bcl-2-associated X protein and activating caspase-3 and caspase-9. *J Trad Chin Med.* **2017**;37(2):229–5. doi:10.1016/s0254-6272(17)30049-3
56. Chen ME, Su CH, Yang JS, et al. Baicalin, baicalein, and lactobacillus rhamnosus jb3 alleviated helicobacter pylori infections in vitro and in Vivo. *J Food Sci.* **2018**;83(12):3118–3125. doi:10.1111/1750-3841.14372
57. Yuan J, Khan SU, Yan J, Lu J, Yang C, Tong Q. Baicalin enhances the efficacy of 5-Fluorouracil in gastric cancer by promoting ROS-mediated ferroptosis. *Biomed Pharmacoth.* **2023**;164:114986. doi:10.1016/j.biopha.2023.114986
58. Zhou Y, Tian L, Long L, Quan M, Liu F, Cao J. Casticin potentiates TRAIL-induced apoptosis of gastric cancer cells through endoplasmic reticulum stress. *PLoS One.* **2013**;8(3):e58855. doi:10.1371/journal.pone.0058855
59. Wang Z, Tang X, Wu X, et al. Cardamonin exerts anti-gastric cancer activity via inhibiting LncRNA-PVT1-STAT3 axis. *Biosci Rep.* **2019**;39:5.
60. Mohammadian F, Pilehvar-Soltanahmadi Y, Alipour S, Dadashpour M, Zarghami N. Chrysin Alters microRNAs expression levels in gastric cancer cells: possible molecular mechanism. *Drug Res.* **2017**;67(9):509–514. doi:10.1055/s-0042-119647
61. Chen L, Li Q, Jiang Z, et al. Chrysin Induced Cell Apoptosis Through H19/let-7a/COPB2 axis in gastric cancer cells and inhibited tumor growth. *Front Oncol.* **2021**;11:651644. doi:10.3389/fonc.2021.651644
62. Zhong X, Liu D, Jiang Z, et al. Chrysin induced cell apoptosis and inhibited invasion through regulation of TET1 expression in gastric cancer cells. *Onco Targets Ther.* **2020**;13:3277–3287. doi:10.2147/OTT.S246031
63. Mohammadian F, Abhari A, Dariushnejad H, Nikanfar A, Pilehvar-Soltanahmadi Y, Zarghami N. Effects of Chrysin-PLGA-PEG nanoparticles on proliferation and gene expression of miRNAs in gastric cancer cell line. *Iran J Cancer Prev.* **2016**;9(4):e4190. doi:10.17795/ijcp-4190
64. Xia Y, Lian S, Khoi PN, et al. Chrysin inhibits tumor promoter-induced MMP-9 expression by blocking AP-1 via suppression of ERK and JNK pathways in gastric cancer cells. *PLoS One.* **2015**;10(4):e0124007. doi:10.1371/journal.pone.0124007
65. Xia Y, Lian S, Khoi PN, et al. Chrysin inhibits cell invasion by inhibition of Recepteur d'origine Nantais via suppressing early growth response-1 and NF- κ B transcription factor activities in gastric cancer cells. *Int j Oncol.* **2015**;46(4):1835–1843. doi:10.3892/ijo.2015.2847

66. Lee H, Lee JH, Jung KH, Hong SS. Deguelin promotes apoptosis and inhibits angiogenesis of gastric cancer. *Oncol Rep.* 2010;24(4):957–963. doi:10.3892/or.2010.957
67. Park JS, Khoi PN, Joo YE, et al. EGCG inhibits recepteur d'origine nantis expression by suppressing Egr-1 in gastric cancer cells. *Int J Oncol.* 2013;42(3):1120–1126. doi:10.3892/ijo.2013.1775
68. Zhu BH, Zhan WH, Li ZR, et al. (-)-Epigallocatechin-3-gallate inhibits growth of gastric cancer by reducing VEGF production and angiogenesis. *World J Gastroenterol.* 2007;13(8):1162–1169. doi:10.3748/wjg.v13.i8.1162
69. Zhu BH, Chen HY, Zhan WH, et al. (-)-Epigallocatechin-3-gallate inhibits VEGF expression induced by IL-6 via Stat3 in gastric cancer. *World J Gastroenterol.* 2011;17(18):2315–2325. doi:10.3748/wjg.v17.i18.2315
70. Liu E, Liang T, Wang X, Ban S, Han L, Li Q. Apoptosis induced by farrerol in human gastric cancer SGC-7901 cells through the mitochondrial-mediated pathway. *Europ J Canc Prev.* 2015;24(5):365–372. doi:10.1097/CEJ.0000000000000104
71. Liu E, Li J, Shi S, et al. Sustained ERK activation-mediated proliferation inhibition of farrerol on human gastric carcinoma cell line by G0/G1-phase cell-cycle arrest. *Europ J Canc Prev.* 2016;25(6):490–499. doi:10.1097/CEJ.0000000000000212
72. Yao JN, Zhang XX, Zhang YZ, et al. Discovery and anticancer evaluation of a formononetin derivative against gastric cancer SGC7901 cells. *Invest New Drugs.* 2019;37(6):1300–1308. doi:10.1007/s10637-019-00767-7
73. Liang X, Wang P, Yang C, et al. Galangin inhibits gastric cancer growth through enhancing STAT3 Mediated ROS production. *Front Pharmacol.* 2021;12:646628. doi:10.3389/fphar.2021.646628
74. Kim DA, Jeon YK, Nam MJ. Galangin induces apoptosis in gastric cancer cells via regulation of ubiquitin carboxy-terminal hydrolase isozyme L1 and glutathione S-transferase P. *Food Chem Toxicol.* 2012;50(3–4):684–688. doi:10.1016/j.fct.2011.11.039
75. Liang XH, Yu MZ, Shi HL, Wu XJ. [Galangin enhances autophagy by inhibiting NF- κ B pathway in gastric cancer MGC-803 cells]. *Zhongguo Zhong yao za zhi.* 2021;46(16):4167–4174. Chinese doi:10.19540/j.cnki.cjcm.20210406.401
76. Yu CY, Su KY, Lee PL, et al. Potential therapeutic role of hispidulin in gastric cancer through induction of apoptosis via NAG-1 Signaling. *Evid Bas Complem Altern Med.* 2013;2013:518301. doi:10.1155/2013/518301
77. Wang Y, Dong H, Zhu M, et al. Icaritin exerts negative effects on human gastric cancer cell invasion and migration by vasodilator-stimulated phosphoprotein via Rac1 pathway. *Eur J Pharmacol.* 2010;635(1–3):40–48. doi:10.1016/j.ejphar.2010.03.017
78. Zhang F, Yin Y, Xu W, et al. Icaritin inhibits gastric cancer cell growth by regulating the hsa_circ_0003159/miR-223-3p/NLRP3 signaling axis. *Hum Exp Toxicol.* 2022;41:9603271221097363. doi:10.1177/09603271221097363
79. Bhosale PB, Vetrivel P, Ha SE, et al. Iridin Induces G2/M phase cell cycle arrest and extrinsic apoptotic cell death through PI3K/AKT signaling pathway in AGS gastric cancer cells. *Molecules.* 2021;26:9. doi:10.3390/molecules26092802
80. Xu Y, Gao CC, Pan ZG, Zhou CW. Iridin sensitizes TRAIL-induced apoptosis via enhancing pro-apoptotic molecules in gastric cancer cells. *Biochem Biophys Res Commun.* 2018;496(3):998–1005. doi:10.1016/j.bbrc.2018.01.003
81. Zhang XR, Wang SY, Sun W, Wei C. Isoliquiritigenin inhibits proliferation and metastasis of MKN28 gastric cancer cells by suppressing the PI3K/AKT/mTOR signaling pathway. *Molec Med Rep.* 2018;18(3):3429–3436. doi:10.3892/mmr.2018.9318
82. Liu J, Ren L, Wang H, Li Z. Isoquercitrin induces endoplasmic reticulum stress and immunogenic cell death in gastric cancer cells. *Biochem Genet.* 2023;61(3):1128–1142. doi:10.1007/s10528-022-10309-1
83. Zhang T, Xiu YH, Xue H, et al. A mechanism of isoorientin-induced apoptosis and migration inhibition in gastric cancer AGS cells. *Pharmaceuticals.* 2022;15(12):1541. doi:10.3390/ph15121541
84. Zhou W, Cao A, Wang L, Wu D. Kurarinone synergizes TRAIL-induced apoptosis in gastric cancer cells. *Cell Biochem Biophys.* 2015;72(1):241–249. doi:10.1007/s12013-014-0444-0
85. Xie R, Gao CC, Yang XZ, et al. Combining TRAIL and liquiritin exerts synergistic effects against human gastric cancer cells and xenograft in nude mice through potentiating apoptosis and ROS generation. *Biomed Pharmacother.* 2017;93:948–960. doi:10.1016/j.biopha.2017.06.095
86. Hao W, Yuan X, Yu L, et al. Licochalcone A-induced human gastric cancer BGC-823 cells apoptosis by regulating ROS-mediated MAPKs and PI3K/AKT signaling pathways. *Sci Rep.* 2015;5:10336. doi:10.1038/srep10336
87. Hongxia G, Xiaojie J, Guangxian L, et al. Licoflavone A suppresses gastric cancer growth and metastasis by blocking the VEGFR-2 signaling pathway. *J Oncol.* 2022;2022:5497991. doi:10.1155/2022/5497991
88. Yajie D, Feng L, Zhaoyan LI, et al. Efficacy of luteolin on the human gastric cancer cell line MKN45 and underlying mechanism. *J Trad Chin Med.* 2023;43(1):34–41. doi:10.19852/j.cnki.jtcm.2023.01.005
89. Zang M, Hu L, Zhang B, et al. Luteolin suppresses angiogenesis and vasculogenic mimicry formation through inhibiting Notch1-VEGF signaling in gastric cancer. *Biochem Biophys Res Commun.* 2017;490(3):913–919. doi:10.1016/j.bbrc.2017.06.140
90. Zang MD, Hu L, Fan ZY, et al. Luteolin suppresses gastric cancer progression by reversing epithelial-mesenchymal transition via suppression of the Notch signaling pathway. *J Transl Med.* 2017;15(1):52. doi:10.1186/s12967-017-1151-6
91. Wu H, Huang M, Liu Y, Shu Y, Liu P. Luteolin induces apoptosis by up-regulating mir-34a in human gastric cancer cells. *Technol Cancer Res Treat.* 2015;14(6):747–755. doi:10.7785/tert.2012.500434
92. Radziejewska I, Borzym-Kluczyk M, Leszczyńska K. Luteolin alters MUC1 extracellular domain, sT antigen, ADAM-17, IL-8, IL-10 and NF- κ B expression in Helicobacter pylori-infected gastric cancer CRL-1739 cells: a preliminary study. *Biomed Rep.* 2021;14(2):19. doi:10.3892/br.2020.1395
93. Lu X, Li Y, Li X, Aisa HA. Luteolin induces apoptosis in vitro through suppressing the MAPK and PI3K signaling pathways in gastric cancer. *Oncol Lett.* 2017;14(2):1993–2000. doi:10.3892/ol.2017.6380
94. Song S, Su Z, Xu H, et al. Correction: luteolin selectively kills STAT3 highly activated gastric cancer cells through enhancing the binding of STAT3 to SHP-1. *Cell Death Dis.* 2018;9(8):787. doi:10.1038/s41419-018-0827-z
95. Lu J, Li G, He K, et al. Luteolin exerts a marked antitumor effect in cMet-overexpressing patient-derived tumor xenograft models of gastric cancer. *J Transl Med.* 2015;13:42.
96. Zhou Y, Ding BZ, Lin YP, Wang HB. MiR-34a, as a suppressor, enhance the susceptibility of gastric cancer cell to luteolin by directly targeting HK1. *Gene.* 2018;644:56–65.
97. Ma J, Pan Z, Du H, et al. Luteolin induces apoptosis by impairing mitochondrial function and targeting the intrinsic apoptosis pathway in gastric cancer cells. *Oncol Lett.* 2023;26(2):327. doi:10.3892/ol.2023.13913

98. Han SH, Lee JH, Woo JS, et al. Myricetin induces apoptosis and autophagy in human gastric cancer cells through inhibition of the PI3K/Akt/mTOR pathway. *Heliyon*. 2022;8(5):e09309. doi:10.1016/j.heliyon.2022.e09309
99. Feng J, Chen X, Wang Y, et al. Myricetin inhibits proliferation and induces apoptosis and cell cycle arrest in gastric cancer cells. *Mol Cell Biochem*. 2015;408(1–2):163–170. doi:10.1007/s11010-015-2492-1
100. Raha S, Kim SM, Lee HJ, et al. Naringin induces lysosomal permeabilization and autophagy cell death in AGS gastric cancer cells. *Am J Chin Med*. 2020;48(3):679–702. doi:10.1142/S0192415X20500342
101. Zhu L, Shi J, Mu M, et al. Naringin inhibits the proliferation, migration, invasion and epithelial-to-mesenchymal transition of gastric cancer cells via the PI3K/AKT signaling pathway. *Alternat Therap Health Med*. 2023;29(1):191–197.
102. Xu C, Huang X, Huang Y, et al. Naringin induces apoptosis of gastric carcinoma cells via blocking the PI3K/AKT pathway and activating pro-death autophagy. *Molec Med Rep*. 2021;24:5. doi:10.3892/mmr.2021.12412
103. Bao L, Liu F, Guo HB, et al. Naringenin inhibits proliferation, migration, and invasion as well as induces apoptosis of gastric cancer SGC7901 cell line by downregulation of AKT pathway. *Tumour Biol*. 2016;37(8):11365–11374. doi:10.1007/s13277-016-5013-2
104. Lee YC, Cheng TH, Lee JS, et al. Nobiletin, a citrus flavonoid, suppresses invasion and migration involving FAK/PI3K/Akt and small GTPase signals in human gastric adenocarcinoma AGS cells. *Mol Cell Biochem*. 2011;347(1–2):103–115. doi:10.1007/s11010-010-0618-z
105. Lee HJ, Venkatarame Gowda Saralamma V, Kim SM, et al. Pectolinarigenin induced cell cycle arrest, autophagy, and apoptosis in gastric cancer cell via PI3K/AKT/mTOR signaling pathway. *Nutrients*. 2018;10:8. doi:10.3390/nu10081043
106. Rong Y, Liu SH, Tang MZ, Yang XJ. Quercetin inhibits the proliferative effect of gastric cancer cells by activating the pyroptosis pathway. *Asian J Surg*. 2023;46:5286–5288. doi:10.1016/j.asjsur.2023.07.051
107. Li F, Wang S, Niu M. Scutellarin inhibits the growth and EMT of gastric cancer cells through regulating PTEN/PI3K Pathway. *Biol Pharmac Bull*. 2021;44(6):780–788. doi:10.1248/bpb.b20-00822
108. Chen XJ, Cui QX, Wang GL, et al. Sanggenon C suppresses tumorigenesis of gastric cancer by blocking ERK-Drp1-mediated mitochondrial fission. *J Natural Prod*. 2022;85(10):2351–2362. doi:10.1021/acs.jnatprod.2c00524
109. Zhang Y, Li Q, Ge Y, et al. Silibinin triggers apoptosis and cell-cycle arrest of SGC7901 cells. *Phytoth Res*. 2013;27(3):397–403. doi:10.1002/ptr.4733
110. Wang T, Gao J, Yu J, Shen L. Synergistic inhibitory effect of wogonin and low-dose paclitaxel on gastric cancer cells and tumor xenografts. *Chin J Can Res*. 2013;25(5):505–513. doi:10.3978/j.issn.1000-9604.2013.08.14
111. Zhao Q, Wang J, Zou MJ, et al. Wogonin potentiates the antitumor effects of low dose 5-fluorouracil against gastric cancer through induction of apoptosis by down-regulation of NF-kappaB and regulation of its metabolism. *Toxicol Lett*. 2010;197(3):201–210. doi:10.1016/j.toxlet.2010.05.019
112. Wang SJ, Zhao JK, Ren S, Sun WW, Zhang WJ, Zhang JN. Wogonin affects proliferation and the energy metabolism of SGC-7901 and A549 cells. *Exp Ther Med*. 2019;17(1):911–918. doi:10.3892/etm.2018.7023
113. Gu Q, Zhu C, Wu X, Peng L, Huang G, Hu R. Wogonoside promotes apoptosis and ER stress in human gastric cancer cells by regulating the IRE1 α pathway. *Exp Ther Med*. 2021;21(4):411. doi:10.3892/etm.2021.9842
114. Wei S, Sun T, Du J, Zhang B, Xiang D, Li W. Xanthohumol, a prenylated flavonoid from Hops, exerts anticancer effects against gastric cancer in vitro. *Oncol Rep*. 2018;40(6):3213–3222. doi:10.3892/or.2018.6723
115. Wang X, Xia M. 5-Hydroxy-3,6,7,8,3',4'-hexamethoxyflavone, a polymethoxyflavone, exerts antitumor effect on PI3K/Akt signaling pathway in human gastric cancer cell BGC-7901. *J Recep Sig Transd Res*. 2016;36(5):471–477. doi:10.3109/10799893.2015.1122046
116. Wang KL, Yu YC, Hsia SM. Perspectives on the role of isoliquiritigenin in cancer. *Cancers*. 2021;13:1.
117. Lee CH, Tsai HY, Chen CL, et al. Isoliquiritigenin inhibits gastric cancer stemness, modulates tumor microenvironment, and suppresses tumor growth through glucose-regulated protein 78 downregulation. *Biomedicines*. 2022;10:6.
118. Babaei G, Aziz SG, Jaghi NZZ. EMT, cancer stem cells and autophagy; The three main axes of metastasis. *Biomed Pharmacothe*. 2021;133:110909.
119. Huang Y, Hong W, Wei X. The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis. *J Hematol Oncol*. 2022;15(1):129.
120. Fong Y, Shen KH, Chiang TA, Shih YW. Acacetin inhibits TPA-induced MMP-2 and u-PA expressions of human lung cancer cells through inactivating JNK signaling pathway and reducing binding activities of NF-kappaB and AP-1. *J Food Sci*. 2010;75(1):H30–8. doi:10.1111/j.1750-3841.2009.01438.x
121. Shen KH, Hung SH, Yin LT, et al. Acacetin, a flavonoid, inhibits the invasion and migration of human prostate cancer DU145 cells via inactivation of the p38 MAPK signaling pathway. *Mol Cell Biochem*. 2010;333(1–2):279–291. doi:10.1007/s11010-009-0229-8
122. He YF, Li BZ, Li Z, et al. Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. *Science*. 2011;333(6047):1303–1307. doi:10.1126/science.1210944
123. Du C, Kurabe N, Matsushima Y, et al. Robust quantitative assessments of cytosine modifications and changes in the expressions of related enzymes in gastric cancer. *Gast Can*. 2015;18(3):516–525. doi:10.1007/s10120-014-0409-4
124. Zhao T, Tang H, Xie L, et al. Scutellaria baicalensis Georgi. (Lamiaceae): a review of its traditional uses, botany, phytochemistry, pharmacology and toxicology. *J Pharm Pharmacol*. 2019;71(9):1353–1369. doi:10.1111/jphp.13129
125. Li J, Cao F, Yin HL, et al. Ferroptosis: past, present and future. *Cell Death Dis*. 2020;11(2):88. doi:10.1038/s41419-020-2298-2
126. Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C, González-Barón M. PI3K/Akt signalling pathway and cancer. *Cancer Treat Rev*. 2004;30(2):193–204. doi:10.1016/j.ctrv.2003.07.007
127. Lien EC, Dibble CC, Tokar A. PI3K signaling in cancer: beyond AKT. *Curr Opin Cell Biol*. 2017;45:62–71. doi:10.1016/j.ceb.2017.02.007
128. Yan R, Xu H, Fu X. Salidroside protects hypoxia-induced injury by up-regulation of miR-210 in rat neural stem cells. *Biomed Pharmacothe*. 2018;103:1490–1497. doi:10.1016/j.biopha.2018.04.184
129. Ren XL, Zhu XH, Li XM, et al. Down-regulation of BTG3 promotes cell proliferation, migration and invasion and predicts survival in gastric cancer. *J Cancer Res Clin Oncol*. 2015;141(3):397–405. doi:10.1007/s00432-014-1826-9
130. Pan G, O'Rourke K, Chinnaiyan AM, et al. The receptor for the cytotoxic ligand TRAIL. *Science*. 1997;276(5309):111–113. doi:10.1126/science.276.5309.111

131. Walczak H, Degli-Esposti MA, Johnson RS, et al. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. *EMBO J*. 1997;16(17):5386–5397. doi:10.1093/emboj/16.17.5386
132. Qin J, Chen J, Peng F, et al. Pharmacological activities and pharmacokinetics of liquiritin: a review. *J Ethnopharmacol*. 2022;293:115257. doi:10.1016/j.jep.2022.115257
133. Zhang G, Liao Y, Yang H, Tao J, Ma L, Zuo X. Irigenin reduces the expression of caspase-3 and matrix metalloproteinases, thus suppressing apoptosis and extracellular matrix degradation in TNF- α -stimulated nucleus pulposus cells. *Chem Biol Interact*. 2021;349:109681.
134. Tomek M, Akiyama T, Dass CR. Role of Bcl-2 in tumour cell survival and implications for pharmacotherapy. *J Pharm Pharmacol*. 2012;64(12):1695–1702. doi:10.1111/j.2042-7158.2012.01526.x
135. Lee S, Rauch J, Kolch W. Targeting MAPK signaling in cancer: mechanisms of drug resistance and sensitivity. *Int J Mol Sci*. 2020;21:3.
136. Guo YJ, Pan WW, Liu SB, Shen ZF, Xu Y, Hu LL. ERK/MAPK signalling pathway and tumorigenesis. *Exp Ther Med*. 2020;19(3):1997–2007. doi:10.3892/etm.2020.8454
137. Ziqubu K, Dlodla PV, Joubert E, et al. Isoorientin: a dietary flavone with the potential to ameliorate diverse metabolic complications. *Pharmacol Res*. 2020;158:104867. doi:10.1016/j.phrs.2020.104867
138. Li X, He S, Ma B. Autophagy and autophagy-related proteins in cancer. *Mol Cancer*. 2020;19(1):12. doi:10.1186/s12943-020-1138-4
139. Levy JMM, Towers CG, Thorburn A. Targeting autophagy in cancer. *Nat Rev Cancer*. 2017;17(9):528–542. doi:10.1038/nrc.2017.53
140. Jiang X, Stockwell BR, Conrad M. Ferroptosis: mechanisms, biology and role in disease. *Nat Rev Mol Cell Biol*. 2021;22(4):266–282. doi:10.1038/s41580-020-00324-8
141. Dixon SJ, Lemberg KM, Lamprecht MR, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. *Cell*. 2012;149(5):1060–1072. doi:10.1016/j.cell.2012.03.042
142. Kovacs SB, Miao EA. Gasdermins: effectors of Pyroptosis. *Trends Cell Biol*. 2017;27(9):673–684. doi:10.1016/j.tcb.2017.05.005
143. Fang Y, Tian S, Pan Y, et al. Pyroptosis: a new frontier in cancer. *Biomed pharmacoth*. 2020;121:109595. doi:10.1016/j.biopha.2019.109595
144. Park HS, Wijerathne CUB, Jeong HY, Seo CS, Ha H, Kwun HJ. Gastroprotective effects of Hwanglyeonhaedok-tang against Helicobacter pylori-induced gastric cell injury. *J Ethnopharmacol*. 2018;216:239–250. doi:10.1016/j.jep.2018.01.025
145. Li P, Hu J, Shi B, Tie J. Baicalein enhanced cisplatin sensitivity of gastric cancer cells by inducing cell apoptosis and autophagy via Akt/mTOR and Nrf2/Keap 1 pathway. *Biochem Biophys Res Commun*. 2020;531(3):320–327. doi:10.1016/j.bbrc.2020.07.045
146. Hou G, Yuan X, Li Y, Hou G, Liu X. Cardamonin, a natural chalcone, reduces 5-fluorouracil resistance of gastric cancer cells through targeting Wnt/ β -catenin signal pathway. *Invest New Drugs*. 2020;38(2):329–339. doi:10.1007/s10637-019-00781-9
147. Han JH, Kim M, Kim HJ, et al. Targeting lactate dehydrogenase A with catechin resensitizes SNU620/5FU gastric cancer cells to 5-Fluorouracil. *Int J Mol Sci*. 2021;22:10. doi:10.3390/ijms22105406
148. Lee S, Lee SK, Jung J. Potentiating activities of chrysin in the therapeutic efficacy of 5-fluorouracil in gastric cancer cells. *Oncol Lett*. 2021;21(1):24. doi:10.3892/ol.2020.12285
149. Lin X, Tian L, Wang L, Li W, Xu Q, Xiao X. Antitumor effects and the underlying mechanism of licochalcone A combined with 5-fluorouracil in gastric cancer cells. *Oncol Lett*. 2017;13(3):1695–1701. doi:10.3892/ol.2017.5614
150. Xu GY, Tang XJ. Troxerutin (TXN) potentiated 5-Fluorouracil (5-Fu) treatment of human gastric cancer through suppressing STAT3/NF- κ B and Bcl-2 signaling pathways. *Biomed Pharmacoth*. 2017;92:95–107. doi:10.1016/j.biopha.2017.04.059
151. Kim TW, Lee SY, Kim M, Cheon C, Ko SG. Kaempferol induces autophagic cell death via IRE1-JNK-CHOP pathway and inhibition of G9a in gastric cancer cells. *Cell Death Dis*. 2018;9(9):875. doi:10.1038/s41419-018-0930-1
152. Wei F, Jiang X, Gao HY, Gao SH. Liquiritin induces apoptosis and autophagy in cisplatin (DDP)-resistant gastric cancer cells in vitro and xenograft nude mice in vivo. *Int j Oncol*. 2017;51(5):1383–1394. doi:10.3892/ijo.2017.4134
153. Wu B, Zhang Q, Shen W, Zhu J. Anti-proliferative and chemosensitizing effects of luteolin on human gastric cancer AGS cell line. *Mol Cell Biochem*. 2008;313(1–2):125–132. doi:10.1007/s11010-008-9749-x
154. Ren LQ, Li Q, Zhang Y. Luteolin suppresses the proliferation of gastric cancer cells and acts in synergy with oxaliplatin. *Biomed Res Int*. 2020;2020:9396512. doi:10.1155/2020/9396512
155. Ma J, Chen X, Zhu X, et al. Luteolin potentiates low-dose oxaliplatin-induced inhibitory effects on cell proliferation in gastric cancer by inducing G(2)/M cell cycle arrest and apoptosis. *Oncol Lett*. 2022;23(1):16. doi:10.3892/ol.2021.13134
156. Zhang H, Zhong X, Zhang X, Shang D, Zhou YI, Zhang C. Enhanced anticancer effect of ABT-737 in combination with naringenin on gastric cancer cells. *Exp Ther Med*. 2016;11(2):669–673. doi:10.3892/etm.2015.2912
157. Yoshimizu N, Otani Y, Saikawa Y, et al. Anti-tumour effects of nobiletin, a citrus flavonoid, on gastric cancer include: antiproliferative effects, induction of apoptosis and cell cycle deregulation. *Aliment Pharmacol Ther*. 2004;20(1):95–101. doi:10.1111/j.1365-2036.2004.02082.x
158. Lei CS, Hou YC, Pai MH, Lin MT, Yeh SL. Effects of quercetin combined with anticancer drugs on metastasis-associated factors of gastric cancer cells: in vitro and in vivo studies. *J Nutr Biochem*. 2018;51:105–113.
159. Ghavami G, Muhammadnejad S, Amanpour S, Sardari S. Bioactivity screening of mulberry leaf extracts and two related flavonoids in combination with cisplatin on human gastric adenocarcinoma cells. *Iran J Pharm Res*. 2020;19(2):371–382. doi:10.22037/ijpr.2020.1101087
160. Li Q, Ren L, Zhang Y, et al. P38 signal transduction pathway has more cofactors on apoptosis of SGC-7901 gastric cancer cells induced by combination of rutin and oxaliplatin. *Biomed Res Int*. 2019;2019:6407210. doi:10.1155/2019/6407210
161. Sun Q, Yuan M, Wang H, et al. PKM2 is the target of a multi-herb-combined decoction during the inhibition of gastric cancer progression. *Front Oncol*. 2021;11:767116. doi:10.3389/fonc.2021.767116
162. Zhou XL, Chen ZD, Zhou YM, Shi RH, Li ZJ. The effect of tartary buckwheat flavonoids in inhibiting the proliferation of MGC80-3 cells during seed germination. *Molecules*. 2019;24:17. doi:10.3390/molecules24173092
163. Hong ZP, Wang LG, Wang HJ, Ye WF, Wang XZ. Wogonin exacerbates the cytotoxic effect of oxaliplatin by inducing nitrosative stress and autophagy in human gastric cancer cells. *Phytomedicine*. 2018;39:168–175. doi:10.1016/j.phymed.2017.12.019
164. Blondy S, David V, Verdier M, Mathonnet M, Perraud A, Christou N. 5-Fluorouracil resistance mechanisms in colorectal cancer: from classical pathways to promising processes. *Can Sci*. 2020;111(9):3142–3154. doi:10.1111/cas.14532
165. Bernatoniene J, Kopustinskiene DM. The Role of Catechins in Cellular Responses to Oxidative Stress. *Molecules*. 2018;23:4. doi:10.3390/molecules23040965

166. Lv P, Man S, Xie L, Ma L, Gao W. Pathogenesis and therapeutic strategy in platinum resistance lung cancer. *Biochim Biophys Acta Rev Cancer*. 1876;2021(1):188577.
167. Xiao X, Oswald JT, Wang T, Zhang W, Li W. Use of anticancer platinum compounds in combination therapies and challenges in drug delivery. *Curr Med Chem*. 2020;27(18):3055–3078. doi:10.2174/0929867325666181105115849

Drug Design, Development and Therapy

Dovepress

Publish your work in this journal

Drug Design, Development and Therapy is an international, peer-reviewed open-access journal that spans the spectrum of drug design and development through to clinical applications. Clinical outcomes, patient safety, and programs for the development and effective, safe, and sustained use of medicines are a feature of the journal, which has also been accepted for indexing on PubMed Central. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/drug-design-development-and-therapy-journal>